All the participants in this study were aged between 40 and 65 and suffered from orthostatic hypotension. Yahom navakot orthostatic hypotension head-up tilt test
Conditions
Interventions
Yahom navakot is administered orally by mixing 1 g of the powder in 50ml of water heated to 35 C before conducting a 70 degree angle of HUT,Yahom navakot is administered orally by mixing 2 g of the
Experimental Drug,Experimental Drug
1 g of Yahom Navakot ,2 g of Yahom Navakot
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: Participants had to be aged between 40 to 65. Their SBP had to decrease by at least 20 mmHg and/or DBP by at least 10 mmHg within 3 min of changing position from supine to upright. The diagnosis of OH was determined following 5 min of rest in the supine position, then the patients stood upright and their BP measurements were repeated on the same arm twice, at 1 and 3 minutes using an automated oscillometric sphygmomanometer with an appropriately sized cuff.
Exclusion criteria
Exclusion criteria: Participants were excluded if they were pregnant or breastfeeding, current use of either hypotension or hypertension medication, and/or an allergic reaction to any of the ingredients in YN. Patients with diseases that create contraindications using a tilt bed include severe anemia, kidney or heart failure, severe mitral valve or aortic valve stenosis, tachycardia, severe proximal cerebral artery stenosis and/or coronary artery disease, prior stroke or myocardial infarction in the past 7 days, or lower extremity fractures were also excluded .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of orthostatic hypotension in the upright position during 70 degree angle of HUT With in 1,2,3 and 5 minute after conducting 70 degree angle of HUT SBP, DBP, MAP, PP and HR were determined in both a supine position, and a 70 degree angle of HUT before and after oral administration of Yahom Navakot | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events not found at the end of the treatment. 30 minutes, 24 and 48 hours after drug administration. Adverse events and vital signs | — |
Countries
Thailand
Contacts
Public ContactPongpun Jittham
Department of Medicine, Faculty of Medicine, Naresuan University
Outcome results
None listed